Market Research on China Recombinant Protein Drug Industry Report, 2014-2017

Submitted by: Submitted by

Views: 83

Words: 640

Pages: 3

Category: Business and Industry

Date Submitted: 11/19/2014 04:25 AM

Report This Essay

ResearchMoz.us include new market research report " China Recombinant Protein Drug Industry, 2014-2017: Market Size, Shares, Growth, Analysis, Trends And Forecast" to its huge collection of research reports.

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014.

View Full Report with TOC at: http://www.researchmoz.us/china-recombinant-protein-drug-industry-report-2014-2017-report.html

The start of recombinant protein drugs in China is not late and common drugs are diversified in variety, for example, recombinant human erythropoietin (rhEPO), recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interferon (rhIFN) have gained market approval in the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO andrecombinant human growth hormone (rhGH) with price advantage took a respective share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and recombinant human interleukin-2/11(rhIL-2/11) was fully localized.

However, as compared with products from leading bio-pharmaceutical enterprises in the United States and Europe, domestic recombinant protein drugs are still characterized by low-end technologies and largely remain in common short-acting areas. And foreign brands still prevail in the markets of recombinant insulin, rhIFN, recombinant coagulation factor and recombinant human follicle-stimulating hormone (rhFSH).

1. Recombinant Insulin Market: In 2013,foreign brands such asNovo Nordisk’s insulin aspart and insulin detemir, Sanofi’s insulin glargine, Eli Lilly’s insulin lispro accounted for 91.4% of recombinant insulin market of Chinese sample hospitals, while domestic insulin e.g. insulin...